| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 185.65 | 11.8% |
| Total Income | 187.75 | 11.3% |
| Expenditure | 125.17 | 17.5% |
| PBT | 62.58 | 0.8% |
| Net Profit | 46.78 | 1.4% |
| OPM | 29.63% | 3.11pp |
| NPM | 24.92% | 2.45pp |
| EPS | 5.82 | 1.9% |
Supriya Lifescience Q3FY25 PAT Jumps 125% YoY to Rs 46.78 Crore
25 Jan 2025 · 25 Jan 2025, 05:08 pm
Summary
Supriya Lifescience Ltd., a cGMP-compliant company with a strong track record in API manufacturing, has reported a significant 125% YoY increase in Profit After Tax (PAT) for Q3 FY25, reaching Rs 46.78 crore. The company's revenue also grew by 33% YoY, amounting to Rs 185.65 crore.
Key Highlights
- 1
Revenue for Q3 FY25 increased by 33% YoY to Rs 185.65 crore
- 2
Gross Profit for Q3 FY25 surged by 45% YoY to Rs 123.87 crore
- 3
EBITDA for Q3 FY25 stood at Rs 68.05 crore with an EBITDA Margin of 36.66%
- 4
PAT for Q3 FY25 jumped by 125% YoY to Rs 46.78 crore
- 5
PAT Margin for Q3 FY25 was 25.2%
Management Comments
Dr. Satish Wagh
Chairman and Whole Time Director, Supriya Lifescience Ltd
Our Q3FY25 results underscore Supriya Lifescience’s commitment to delivering value through operational excellence and strategic growth initiatives. The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments. The steady improvement in our EBITDA and PAT margins, reaching 37% and 25% respectively, highlights our ability to maintain profitability while investing in sustainable growth.
Informational and educational content only. Not investment advice.